AbbVie
ABBV
1,996 hedge funds and large institutions have $99.2B invested in AbbVie in 2018 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 819 increasing their positions, 831 reducing their positions, and 82 closing their positions.
1% less funds holding
Funds holding: 2,016 → 1,996 (-20)
1% less first-time investments, than exits
New positions opened: 81 | Existing positions closed: 82
1% less repeat investments, than reductions
Existing positions increased: 819 | Existing positions reduced: 831
3.22% less ownership
Funds ownership: 70.73% → 67.51% (-3.2%)
7% less capital invested
Capital invested by funds: $106B → $99.2B (-$6.94B)
7% less funds holding in top 10
Funds holding in top 10: 137 → 128 (-9)
26% less call options, than puts
Call options by funds: $984M | Put options by funds: $1.33B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$368M |
| 2 |
Millennium Management
New York
|
+$182M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$131M |
| 4 |
AT
AMF Tjänstepension
Stockholm,
Sweden
|
+$119M |
| 5 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$117M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.1B |
| 2 |
Jennison Associates
New York
|
-$583M |
| 3 |
BlackRock
New York
|
-$375M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$353M |
| 5 |
State Street
Boston,
Massachusetts
|
-$273M |
ABBV Hedge Fund Activity: Q2 2018 in Review
1,996 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2018, worth a combined $99.2B — down 6.5% from $106B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of ABBV and 81 opened new positions — a net loss of 1 holder — while 831 trimmed existing stakes and 819 added.
The largest buyer was Arrowstreet Capital, adding an estimated $368M. The largest seller was Fidelity Investments, cutting an estimated $1.1B.
- 1,996 institutional investors held AbbVie (ABBV) as of Q2 2018, down from 2,016 in Q1 2018.
- Funds reported $99.2B of AbbVie stock for Q2 2018, down 6.5% quarter-over-quarter.
- 81 funds opened new AbbVie positions in Q2 2018 and 82 closed out, a net change of -1 holder.
- The largest AbbVie buyer in Q2 2018 was Arrowstreet Capital, an estimated $368M added.
- The largest AbbVie seller in Q2 2018 was Fidelity Investments, an estimated $1.1B sold.
Based on aggregated 13F filings for Q2 2018.